| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 分部间抵销(元) | -10,125,940.66 | - | -15,549,614.47 | - | -10,021,271.82 |
| 医药制造业务(元) | 831,842,219.71 | - | 783,315,942.27 | - | 677,174,237.93 |
| 儿科(元) | - | 188,169,688.60 | - | 150,852,727.84 | - |
| 妇科(元) | - | 92,369,573.94 | - | 108,933,556.34 | - |
| 骨伤科(元) | - | 358,927,489.58 | - | 367,515,936.71 | - |
| 呼吸系统用药(元) | - | 179,609,459.87 | - | 140,364,618.01 | - |
| 抗感染(元) | - | 81,854,461.84 | - | 96,281,386.28 | - |
| 心脑血管(元) | - | 384,553,335.27 | - | 448,951,842.60 | - |
| 其他(元) | 61,893,700.28 | 283,965,368.71 | 63,398,219.98 | 437,830,786.32 | 185,214,326.12 |
| 营业成本(元) | |||||
| 分部间抵销(元) | -17,353,686.47 | - | -20,959,703.54 | - | -12,549,860.33 |
| 医药制造业务(元) | 210,170,807.42 | - | 226,643,546.89 | - | 162,219,956.75 |
| 儿科(元) | - | 65,674,949.83 | - | 54,114,821.97 | - |
| 妇科(元) | - | 19,158,533.85 | - | 21,768,898.94 | - |
| 骨伤科(元) | - | 52,382,093.23 | - | 53,240,901.79 | - |
| 呼吸系统用药(元) | - | 49,482,187.26 | - | 39,901,624.30 | - |
| 抗感染(元) | - | 52,951,072.53 | - | 59,893,428.43 | - |
| 心脑血管(元) | - | 100,102,496.04 | - | 78,102,292.99 | - |
| 其他(元) | 47,633,126.83 | 145,281,251.56 | 47,042,636.00 | 268,625,889.54 | 134,703,262.88 |
| 毛利(元) | |||||
| 分部间抵销(元) | 7,227,745.81 | - | 5,410,089.07 | - | 2,528,588.51 |
| 医药制造业务(元) | 621,671,412.29 | - | 556,672,395.38 | - | 514,954,281.18 |
| 儿科(元) | - | 122,494,738.77 | - | 96,737,905.87 | - |
| 妇科(元) | - | 73,211,040.09 | - | 87,164,657.40 | - |
| 骨伤科(元) | - | 306,545,396.35 | - | 314,275,034.92 | - |
| 呼吸系统用药(元) | - | 130,127,272.61 | - | 100,462,993.71 | - |
| 抗感染(元) | - | 28,903,389.31 | - | 36,387,957.85 | - |
| 心脑血管(元) | - | 284,450,839.23 | - | 370,849,549.61 | - |
| 其他(元) | 14,260,573.45 | 138,684,117.15 | 16,355,583.98 | 169,204,896.78 | 50,511,063.24 |
| 毛利率(%) | |||||
| 分部间抵销(%) | -71.38 | - | -34.79 | - | -25.23 |
| 医药制造业务(%) | 74.73 | - | 71.07 | - | 76.04 |
| 儿科(%) | - | 65.10 | - | 64.13 | - |
| 妇科(%) | - | 79.26 | - | 80.02 | - |
| 骨伤科(%) | - | 85.41 | - | 85.51 | - |
| 呼吸系统用药(%) | - | 72.45 | - | 71.57 | - |
| 抗感染(%) | - | 35.31 | - | 37.79 | - |
| 心脑血管(%) | - | 73.97 | - | 82.60 | - |
| 其他(%) | 23.04 | 48.84 | 25.80 | 38.65 | 27.27 |
| 收入构成(%) | |||||
| 分部间抵销(%) | -1.15 | - | -1.87 | - | -1.18 |
| 医药制造业务(%) | 94.14 | - | 94.24 | - | 79.45 |
| 儿科(%) | - | 11.99 | - | 8.62 | - |
| 妇科(%) | - | 5.89 | - | 6.22 | - |
| 骨伤科(%) | - | 22.87 | - | 20.99 | - |
| 呼吸系统用药(%) | - | 11.44 | - | 8.02 | - |
| 抗感染(%) | - | 5.22 | - | 5.50 | - |
| 心脑血管(%) | - | 24.50 | - | 25.64 | - |
| 其他(%) | 7.00 | 18.09 | 7.63 | 25.01 | 21.73 |
| 毛利构成(%) | |||||
| 分部间抵销(%) | 1.12 | - | 0.94 | - | 0.45 |
| 医药制造业务(%) | 96.66 | - | 96.24 | - | 90.66 |
| 儿科(%) | - | 11.30 | - | 8.23 | - |
| 妇科(%) | - | 6.75 | - | 7.42 | - |
| 骨伤科(%) | - | 28.27 | - | 26.74 | - |
| 呼吸系统用药(%) | - | 12.00 | - | 8.55 | - |
| 抗感染(%) | - | 2.67 | - | 3.10 | - |
| 心脑血管(%) | - | 26.23 | - | 31.56 | - |
| 其他(%) | 2.22 | 12.79 | 2.83 | 14.40 | 8.89 |